Company & Sponsor Intelligence

Yonsei University

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials6

Recruiting2

Completed4

Countries1

Therapeutic footprint

epilepsyother_neurologyparkinsonssleep_disordersstroke

Indexed studies

NCT00968136Short-term Ketogenic Diet as Compared With Conventional Long-term Trial in Refractory Infantile Spasms: A Randomized, Controlled Study
other_neurology · COMPLETED

NCT02964052Selection Criteria in Endovascular Thrombectomy and Thrombolytic Therapy (SECRET) Study: Development of Patient Selection Criteria Using CT Images and Accompanying Diseases for Efficient Intravenous Thrombolytic and Intra-arterial Recanalization Therapy in Acute Ischemic Stroke
stroke · South KoreaCOMPLETED

NCT07804381Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's Disease
parkinsons · PHASE2

NCT06677970Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Pressure Control 2 (OPTIMAL-BP 2)
stroke · South KoreaPHASE3

NCT06339853Study of Efficacy of Digital Cognitive Behavioral Therapy With Wearable Device for Insomnia
sleep_disorders · South KoreaNA

NCT03198949A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)
epilepsy · South KoreaPHASE2

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →